Arvinas to Participate in Upcoming Investor Conferences
Arvinas (Nasdaq: ARVN), a clinical-stage biotechnology company focused on targeted protein degradation, has announced its participation in three major investor conferences in March 2025:
- Leerink Partners Global Healthcare Conference on March 11, featuring a fireside chat with CFO Andrew Saik and CBO Randy Teel, Ph.D.
- Jefferies Biotech on the Beach Summit on March 12, where management will conduct one-on-one meetings
- Barclays 27th Annual Global Healthcare Conference on March 13, including another fireside chat presentation
Live audio webcasts will be available for the Leerink and Barclays presentations through the company's website.
Arvinas (Nasdaq: ARVN), un'azienda biotecnologica in fase clinica focalizzata sulla degradazione mirata delle proteine, ha annunciato la sua partecipazione a tre importanti conferenze per investitori a marzo 2025:
- Conferenza Globale sulla Salute di Leerink Partners l'11 marzo, con una chiacchierata informale con il CFO Andrew Saik e il CBO Randy Teel, Ph.D.
- Summit Jefferies Biotech on the Beach il 12 marzo, dove la direzione condurrà incontri one-to-one
- 27a Conferenza Globale Annuale sulla Salute di Barclays il 13 marzo, che includerà un'altra presentazione in formato chiacchierata informale
Le trasmissioni audio in diretta saranno disponibili per le presentazioni di Leerink e Barclays attraverso il sito web dell'azienda.
Arvinas (Nasdaq: ARVN), una empresa biotecnológica en etapa clínica centrada en la degradación selectiva de proteínas, ha anunciado su participación en tres importantes conferencias para inversores en marzo de 2025:
- Conferencia Global de Salud de Leerink Partners el 11 de marzo, con una charla informal con el CFO Andrew Saik y el CBO Randy Teel, Ph.D.
- Cumbre Jefferies Biotech on the Beach el 12 de marzo, donde la dirección llevará a cabo reuniones uno a uno
- 27ª Conferencia Anual Global de Salud de Barclays el 13 de marzo, que incluirá otra presentación en formato de charla informal
Las transmisiones de audio en vivo estarán disponibles para las presentaciones de Leerink y Barclays a través del sitio web de la empresa.
Arvinas (Nasdaq: ARVN), 표적 단백질 분해에 중점을 둔 임상 단계 생명공학 회사가 2025년 3월에 열리는 세 가지 주요 투자자 회의에 참여한다고 발표했습니다:
- 리어링크 파트너스 글로벌 헬스케어 컨퍼런스 3월 11일, CFO Andrew Saik 및 CBO Randy Teel, Ph.D.와의 대화 세션이 진행됩니다.
- 제퍼리스 바이오텍 온 더 비치 서밋 3월 12일, 경영진이 일대일 미팅을 진행합니다.
- 바클레이스 제27회 연례 글로벌 헬스케어 컨퍼런스 3월 13일, 또 다른 대화 세션 발표가 포함됩니다.
리어링크 및 바클레이스 발표에 대한 라이브 오디오 웹캐스트는 회사 웹사이트를 통해 제공됩니다.
Arvinas (Nasdaq: ARVN), une entreprise de biotechnologie en phase clinique axée sur la dégradation ciblée des protéines, a annoncé sa participation à trois grandes conférences pour investisseurs en mars 2025 :
- Conférence Mondiale de la Santé de Leerink Partners le 11 mars, avec un échange informel avec le CFO Andrew Saik et le CBO Randy Teel, Ph.D.
- Sommet Jefferies Biotech on the Beach le 12 mars, où la direction tiendra des réunions individuelles
- 27ème Conférence Annuelle Mondiale de la Santé de Barclays le 13 mars, comprenant une autre présentation sous forme de conversation informelle
Des webdiffusions audio en direct seront disponibles pour les présentations de Leerink et Barclays via le site internet de l'entreprise.
Arvinas (Nasdaq: ARVN), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf gezielte Proteinabbau konzentriert, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im März 2025 angekündigt:
- Leerink Partners Global Healthcare Conference am 11. März, mit einem informellen Gespräch mit CFO Andrew Saik und CBO Randy Teel, Ph.D.
- Jefferies Biotech on the Beach Summit am 12. März, bei dem das Management Einzelgespräche führen wird
- 27. Barclays Annual Global Healthcare Conference am 13. März, einschließlich einer weiteren informellen Gesprächspräsentation
Live-Audio-Webcasts werden für die Präsentationen von Leerink und Barclays über die Website des Unternehmens verfügbar sein.
- None.
- None.
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences:
- Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11. Andrew Saik, Chief Financial Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.
- Jefferies Biotech on the Beach Summit on Wednesday, March 12. Andrew Saik, Chief Financial Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in one-on-one meetings.
- Barclays 27th Annual Global Healthcare Conference on Thursday, March 13. Andrew Saik, Chief Financial Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.comand connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
When is Arvinas (ARVN) presenting at the Leerink Partners Conference 2025?
Which investor conferences is Arvinas (ARVN) attending in March 2025?
How can investors access Arvinas (ARVN) conference presentations in March 2025?
What type of meetings will Arvinas (ARVN) hold at the Jefferies Biotech Summit 2025?
